Company: SCLXW
Filing Date: 2025-01-17
Form Type: 10-Q
Source: 0000950170-25-006755
Chunk: 325

Company: Scilex Holding Co
Filing Date: 2025-01-17
Form: 10-Q
Item: Item 8
Chunk 325
---
 partially offset by an increase in rebates.

Cost of Revenue

Cost of revenue for the three months ended September 30, 2024 and 2023 was $3.8 million and $3.4 million, respectively. The increase of $0.4 million was primarily due to an increase in gross revenue of ELYXYB and GLOPERBA, partially offset by a decrease in logistics costs due to no air shipments used during the three months ended September 30, 2024 compared to the three months ended September 30, 2023.

Research and Development Expenses

The following table summarizes research and development expenses by project for the three months ended September 30, 2024 and 2023 (in thousands):

 47

    Three Months Ended September 30,

    2024

    2023

    Increase (Decrease)

    SP-102

    Contracted R&D
     
    $
    82

    $
    965

    $
    (883
    )

    Personnel

    149

    63

    86

    Other

    14

    19

    (5
    )

    Total SP-102

    245

    1,047

    (802
    )

    SP-103

    Contracted R&D

    1,160

    910

    250

    Personnel

    205

    286

    (81
    )

    Other

    41

    74

    (33
    )

    Total SP-103

    1,406

    1,270

    136

    SP-104

    Contracted R&D

    3

    312

    (309
    )

    Personnel

    (2
    )

    155

    (157
    )

    Other

    (30
    )

    41

    (71
    )

    Total SP-104

    (29
    )

    508

    (537
    )

    GLOPERBA

    Contracted R&D

    94

    173

    (79
    )

    Personnel

    132

    182

    (50
    )

    Other

    32

    28

    4

    Total GLOPERBA

    258

    383

    (125
    )

    ELY